Development of a scheme of treatment measures for complex respiratory diseases in cats
Open Access
- 27 November 2025
- journal article
- Published by Kharkiv Entomological Society in Veterinary Science, Technologies of Animal Husbandry and Nature Management
- Vol. 12, 66
Abstract
The article presents the results of a comparison of the therapeutic efficacy of two therapeutic regimens for complex respiratory diseases in cats. The etiology of complex respiratory diseases in cats is complex and can be caused byseveral viral and bacterial pathogens simultaneously. The most common co-infections are primary pathogens such as feline herpesvirus-1, feline calicivirus, Bordetella bronchiseptica, Chlamydia felis, and Mycoplasma felis. The presence of co-infections may result in more severe clinical signs than infections caused by a single pathogen. Most researchers report the difficulty of treating associated respiratory diseases in cats. The aim of our study was to compare therapeutic regimens using specific serum and the primary use of agents that affect the viral pathogen and the immune system in the treatment of respiratory co-infections in cats. The study involved 12 cats aged 4-8 months, which were treated at the veterinary clinic in Apostolovo, Dnipropetrovsk region during 2025. The diagnosis of viral respiratory infections was confirmed by standard rapid tests based on immunochromatography. Bordetelliosis was confirmed bacteriologically by examining oropharyngeal swabs and transnasal wash samples according to standard methods. One group of animals (n=6) received a treatment regimen without the use of immunostimulating and antiviral drugs. Animals of the control group (n=6) received immunostimulating drugs “Melavit” (manufacturer PJSC Ukrzoovetprompostach, Ukraine) and “Placestim” (manufacturer Vet Line, Ukraine). Also, the antiviral drug “Albuvir” (manufacturer NPP Agrovet, Ukraine) was added to the optimized treatment regimen. The primary use of an antiviral drug and immunomodulators in a comprehensive treatment regimen for respiratory co-infections in cats compared to the use of specific serum showed a higher therapeutic effect. In animals treated according to the developed scheme, clinical recovery occurred 10-12 days after the start of treatment. During this period, signs of purulent conjunctivitis were absent, breathing improved, and wheezing was not heard.Keywords
This publication has 20 references indexed in Scilit:
- Feline respiratory disease. Part 1: common causes and reaching a diagnosisIn Practice, 2023
- Causes and Lesions of Fatal Pneumonia in Domestic CatsJournal of Comparative Pathology, 2021
- Feline Infectious Respiratory Disease2021
- Limited cross‐species transmission and absence of mutations associated with SARS‐CoV‐2 adaptation in cats: A case study of infection in a small household settingTransboundary and Emerging Diseases, 2021
- Effects of famciclovir in cats with spontaneous acute upper respiratory tract diseaseJournal of Feline Medicine and Surgery, 2019
- Antimicrobial Resistance in Bordetella bronchisepticaMicrobiology Spectrum, 2018
- Patterns of antimicrobial agent prescription in a sentinel population of canine and feline veterinary practices in the United KingdomThe Veterinary Journal, 2017
- Feline calicivirus and other respiratory pathogens in cats with Feline calicivirus-related symptoms and in clinically healthy cats in SwitzerlandBMC Veterinary Research, 2015
- Factors associated with upper respiratory tract disease caused by feline herpesvirus, feline calicivirus, Chlamydophila felis and Bordetella bronchiseptica in cats: experience from 218 European catteriesVeterinary Record, 2005
- A Study of Feline Upper Respiratory Tract Disease with Reference to Prevalence and Risk Factors for Infection with Feline Calicivirus and Feline HerpesvirusJournal of Feline Medicine and Surgery, 2000